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httpExperience with the GORE EXCLUDER iliac
branch endoprosthesis for common iliac artery
aneurysms
Steven M. M. van Sterkenburg, MD,a Jan M. M. Heyligers, MD, PhD,b Mathijs van Bladel, BSc,a
Hence J. Verhagen, MD, PhD,c Daniël Eefting, MD, PhD,d Marc R. van Sambeek, MD, PhD,e
Clark J. Zeebregts, MD, PhD,f and Michel M. P. J. Reijnen, MD, PhD,a for the Dutch IBE
Collaboration, Arnhem, Tilburg, Rotterdam, The Hague, Eindhoven, and Groningen, The Netherlands
Objective: In this study, we analyzed the procedural success and early outcome of endovascular treatment of a multicenter
cohort of patients with common iliac artery (CIA) aneurysms treated with the new GORE EXCLUDER (W. L. Gore &
Associates, Flagstaff, Ariz) iliac branch endoprosthesis (IBE).
Methods: A retrospective cohort analysis was performed in 13 sites in The Netherlands. Anatomic, demographic, proce-
dural, and follow-up data were assessed from hospital records.
Results: From November 2013 to December 2014, 51 CIA aneurysms were treated with an IBE in 46 patients.
The median diameter of the treated aneurysm was 40.5 (range, 25.0-90.0) mm. The mean procedural time was
1986 56 minutes. All but one implantation were successful; two type Ib endoleaks were noticed, resulting in a procedural
success rate of 93.5%. The two type Ib endoleaks spontaneously disappeared at 30 days. There was no 30-day mortality.
Ipsilateral buttock claudication was present in only two cases at 30 days and disappeared during follow-up. The incidence
of reported erectile dysfunction was low and severe ischemic complications were absent. After a mean follow-up of
6 months, data on 17 treated aneurysms were available. Two showed a stable diameter, whereas 15 showed a mean
decrease of 3.9 6 2.2 mm (P < .001). Reinterventions were performed in two patients (7.1%). The 6-month primary
patency of the internal component of the IBE device was 94%.
Conclusions: The use of the GORE EXCLUDER IBE device for CIA aneurysms is related to high procedural success, high
patency rates, and low reintervention rates at short-term follow-up. Prospective data with longer follow-up are awaited to
establish the role of the device in the treatment algorithm of CIA aneurysms. (J Vasc Surg 2016;63:1451-7.)Endovascular aortic aneurysm repair (EVAR) of
abdominal aneurysms has gradually replaced open surgical
repair and is now an established treatment modality. EVAR
results in reduced operative blood loss, reduced length of
stay in the intensive care unit, and is related to lower 30-
day mortality rates.1 The applicability of standard EVAR
has been challenged by involvement of the visceral arteries
and/or aneurysm extension into the iliac arteries. An iso-
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://dx.doi.org/10.1016/j.jvs.2016.01.021uncommon, but in relation to an abdominal aneurysm, it
is found in 20% to 40% of cases.2
Various strategies have been applied to enable EVAR in
CIA aneurysms. Intentional occlusion of the hypogastric
artery by coiling and covering might be safe, but it can
cause gluteal claudication (16%-55%) and erectile dysfunc-
tion (10%-46%), or even more devastating complications
such as colonic or spinal cord ischemia.3-5 Better results
might be achieved by only covering the internal iliac artery
(IIA), but this technique can result in a persistent type II
endoleak with uncertain long-term results.6 To reduce
the incidence of ischemic complications, other techniques
have been used, including the use of bell-bottom limbs
and the off-label use of endografts.7,8 The Zenith Iliac
branched device (Cook, Brisbane, Queensland, Australia)
was the ﬁrst dedicated device to preserve hypogastric ﬂow
after EVAR of CIA aneurysms. The device consists of a sin-
gle component and is used with various types of grafts to
extend into the IIA.9 Results are encouraging, but endo-
leak rates of 3% to 30% and occlusion rates up to 12%
have been described.10-12 These data might partly reﬂect
a general early learning curve for iliac branch devices
(IBDs). More recently, the GORE EXCLUDER iliac
branch endoprosthesis (IBE; W. L. Gore & Associates,
Flagstaff, Ariz) was developed. The system is based on
the Excluder platform and is combined with a dedicated in-
ternal iliac component. Conformité Européenne mark for1451
Fig 1. Image of the GORE EXCLUDER iliac branch endopros-
thesis (IBE). Image courtesy of W. L. Gore & Associates.
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we describe a multicenter national retrospective cohort
study with the use of the IBE device in CIA aneurysms.
The primary focus of this study was to evaluate procedural
success and additionally to determine short-term iliac
branch patency. Secondary outcomes were patency, clinical
symptoms of ischemia, and CIA aneurysm diameters.
METHODS
All Dutch centers with experience in IBE device im-
plantation were invited to collaborate in this study
(Supplementary Table). Retrospective data were captured
in a database. Anatomical details were measured from the
computed tomography (CT) scans by the vascular surgeon
or interventional radiologist. Each operator was responsible
for sizing and planning of their own procedures. Demo-
graphic, procedural, and postprocedural data were assessed
from hospital records and coded in the database. Results
are reported according to the reporting standards for
EVAR.13 Retrospective “patient ﬁles” research is not in
scope of the Dutch Wet Mensgebonden Onderzoek: law
human bound research and institutional review board
approval was therefore not required. As a consequence,
patient informed consent was not obtained. Patient data
were analyzed anonymously.
Treatment. The IBE is designed to provide endovas-
cular treatment of CIA or aortoiliac aneurysms as a dedi-
cated device to be used in conjunction with the GORE
EXCLUDER endoprosthesis (Fig 1). Anatomical limita-
tions are described in the instructions for use (IFU) and
include a CIA diameter of at least 17 mm proximal of the
implantation zone of the IBE. The nonaneurysmal length
of the external iliac artery (EIA) should be at least 10 mm
with a diameter of 6.5 to 13.5 mm, or with a diameter
range of 6.5 to 25 mm in case an extension is used. The
diameter of the IIA should be 6.5 to 13.5 mm with a distal
sealing zone length of at least 10 mm. There is no limita-
tion regarding the length of the CIA. A minimal distance of
165 mm between the lowest renal artery and the iliac
bifurcation is required. The system is introduced through a
16-F sheath and is designed to achieve high conformability
and sealing in tortuous iliac arteries. The IBE device is
introduced over a stiff guide wire. The internal iliac branch
is preloaded with a small removable guide wire tube, which
is used to snare a crossover guide wire to the contralateral
femoral site. Subsequently, the IBE system is introduced
over the stiff and the crossover wire, with special attention
for adequate position of the two wires. If necessary, the
two-stage IBE deployment system offers repositionability
of either distal movement or 90 in either direction at the
level of the IIA. After the ﬁrst step deployment and proper
positioning of the IBE body, a contralateral ﬂexible 12-F
sheath is introduced over the crossover wire and posi-
tioned into the internal iliac limb of the IBE. A second wire
is used to catheterize the IIA, and after replacement with a
stiff wire, the dedicated iliac component is correctly posi-
tioned and deployed, followed by the second step of
deployment of the IBE leg into the EIA. In case ofaortoiliac aneurysms, a standard Excluder device is placed
via the contralateral site using a GORE EXCLUDER
bridging stent with the IBE. A case example is presented
in Fig 2. Another case example is presented in Fig 3 to
illustrate the deployed IBE device with the crossover
sheath in the body of the device. Follow-up was con-
ducted according to the local protocols of the collaborating
sites.
Deﬁnitions. The primary outcome of the study was
procedural success of implanting, deﬁned as the successful
implantation of the IBE device with a patent side branch
without a type I or III endoleak at completion angiog-
raphy. Secondary outcomes were patency at 30 days and
ﬁnal follow-up visit, change in CIA aneurysm diameter,
and clinical symptoms of ischemia. Patency was deﬁned as
the absence of thrombosis assessed using either CT or
duplex ultrasound. A stenosis was deﬁned as a peak systolic
velocity ratio >2.5, measured using duplex ultrasound
scanning or >50% luminal narrowing on CT scan. The
change in CIA diameter (preprocedure vs follow-up) was
deﬁned as the absolute difference between time points,
measured on CT scan or duplex ultrasound, whichever is
available. Symptoms of ischemia included patient-reported
Fig 2. a, Transversal slide of the preoperative contrast-enhanced computed tomography (CT) image of a 77-year-old
male patient showing bilateral common iliac artery (CIA) aneurysms of 63 and 48 mm on the right and left side,
respectively. b, Procedural angiography of the patient. c, Completion angiography after placement of a GORE
EXCLUDER iliac branch endoprosthesis (IBE) device at the right side and coil-and-covering on the left side, showing
a complete exclusion of the CIA aneurysms and patent ﬂow through the right-sided internal iliac artery.
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spinal ischemia. Other outcome measures were procedural
time, hospitalization time, major and minor adverse events,
and aneurysm-related and overall mortality.
Statistical analysis. Continuous variables are pre-
sented as mean and standard deviation or median and
range when appropriate, and categorical variables as num-
ber and percentage. The Shapiro-Wilk test was used
to examine if continuous variables followed the normal
distribution. If not normally distributed, variables were log-
transformed before testing. Repeated measures analysis of
variance were used to compare diameters between differenttime points. Two-sided P values <.05 were considered
statistically signiﬁcant. All statistical analyses were per-
formed using IBM SPSS Statistics for Windows, Version
21.0 (IBM Corp, Armonk, NY).RESULTS
From November 2013 to December 2014, a total of
51 CIA aneurysms were treated with an IBE in the partici-
pating centers in 46 patients with a mean age of 70.2 6
8.5 years. Overall, 64 IBE devices were implanted in The
Netherlands during the study period. Forty-ﬁve patients
Fig 3. a and b, Procedural ﬂuoroscopy to illustrate the deployed iliac branch endoprosthesis (IBE) device with the
cross-over sheath in the body of the device.
Table I. Anatomical characteristic of the cohort of 46
patients with a CIA aneurysm treated with the GORE
EXCLUDER iliac branch endoprosthesis (IBE) device
Characteristic Size (range), mm
Maximum diameter right CIA 39 (12-90)
Maximum diameter left CIA 31 (12-73)
Length right CIA 70 (44-182)
Length left CIA 68 (40-155)
Maximum diameter right IIA 10 (3-18)
Maximum diameter left IIA 10 (6-21)
Maximum diameter right EIA 12 (9-17)
Maximum diameter left EIA 12 (7-15)
Diameter infrarenal aortic neck 22 (18-30)
Maximum diameter infrarenal aorta 45 (19-80)
CIA, Common iliac artery; EIA, external iliac artery; IIA, internal iliac
artery.
Data are presented as median and range.
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setting but two (4.3%) were considered symptomatic.
Anatomical characteristics are depicted in Table I. The
treated CIA aneurysm was located at the right side in 27
cases (58.7%), and ﬁve patients were treated with a bilateral
IBE (10.9%). The median (range) diameter of the treated
CIA aneurysm was 40.5 (25.0-90.0) mm. In 15 cases
(32.6%), the infrarenal aorta had a diameter of $55 mm,
and 19 others (41%) had an aortic diameter of $30 to
55 mm. In one patient, the distal landing zone in the
IIA was less than the required 10 mm in length. The distal
landing zone in the EIA was always >10 mm in length. In
seven patients (15.6%), the anatomy of the aneurysm was
outside the IFU for the IBE device.
Preoperatively, ﬁve patients suffered from intermittent
claudication. One patient had claudication of the buttock
and four patients had claudication of the thigh or calf, or
a combination of both. The preoperative symptoms were
ipsilateral of the IBE-treated side in 2 patients, contralateral
in 1 patient, and unknown in 2 patients. One patient com-
plained of erectile dysfunction, but information on erectile
function was missing in 23 cases. Antihypertensive drugs
were used by 60.9% (n ¼ 28), platelet inhibitors by
69.6% (n ¼ 32), coumarin derivates by 23.9% (n ¼ 11),
and statins by 70.1% (n ¼ 35) of cases. The American
Society of Anesthesiologists classiﬁcation was 1, 2, 3, and
4 in, respectively, 1, 24, 15, and 1 case and was missing
in the remaining ﬁve cases.
Procedure. Most patients (n ¼ 44; 95.6%) received
surgery under general anesthesia and the other two under
local and regional anesthesia, respectively. Access was
acquired by surgical cutdown in 43 patients (93.5%) andpercutaneous in the remaining patients. The contralateral
IIA was patent and preserved in 29 patients (63.0%),
embolized before the procedure in 2 patients (4.3%),
embolized and overstented during the procedure in 7 pa-
tients (15.2%), and not patent before the procedure and
overstented during the procedure in 3 patients (6.5%).
The decision-making process on the management of the
contralateral IIA was dependent on local protocols and the
individual surgeon. In one patient, it was not possible to
implant the IBE. In that case, the internal component
dislocated during placement and an attempt to implant a
second one failed. Embolization and overstenting was
performed instead. In the remaining ﬁve patients, both IIA







Mortality 0 (0) 1 (4)
Reinterventions 0 (0) 2 (7)
External iliac limb stenosis/occlusion 1 (3) 1 (4)
Internal iliac limb stenosis/occlusion 1 (3) 2 (7)
Endoleak 6 (15) 5 (18)
Type Ib 0 (0) 1 (4)
Type II 5 (13) 4 (14)
Unknown 1 (3) 0 (0)
Intermittent buttock claudication
Contralateral 2 (5) 0 (0)
Ipsilateral 2 (5) 1 (4)
Erectile dysfunction 1 (3) 2 (7)
Data are presented as number (%).
JOURNAL OF VASCULAR SURGERY
Volume 63, Number 6 van Sterkenburg et al 1455were treated with an IBE device. In six patients, the
IBE was placed for a CIA aneurysm without the addition of
a GORE EXCLUDER bifurcated aortic endograft. No
conversions to open repair were needed.
There were six residual endoleaks in ﬁve patients at the
end of the procedure, of which 3 type II, 2 type Ib, and 1
case in which the endoleak could not be deﬁned. The two
type Ib endoleaks, derived from the IBE component, were
considered minor and left untreated. The diameters of
the IIA were 10 and 11 mm, respectively, and treated
with a 14-mm iliac component. The landing zones were
>10 mm in both cases, with circular calcium in one of
them. These two procedural type Ib endoleaks and one
implant failure rendered the procedural success rate to be
93.5%. The overall mean surgery time was 198.3 6 56.2
minutes, with a mean ﬂuoroscopy time of 41.5 6 14.4
minutes. The median (range) time of hospitalization was
3.0 (2.0-8.0) days. At discharge, 28.3% of the patients
(n ¼ 13) were prescribed coumarin derivates, 78.3% (n ¼
36) platelet inhibitors, 84.8% (n ¼ 39) statins, and 67.4%
(n¼ 31) antihypertensive drugs. Three patients had adverse
events: 1 had atrial ﬁbrillation and delirium, 1 had seroma of
both groins, and 1 had decubitus.
Thirty-day outcome. At 30-day follow-up, no rein-
terventions were performed. There was one occlusion of
the treated IIA, which was observed on a CT angiography
scan during admission of a patient who was treated inside
the IFU. Because this patient did not have any complaints,
no reintervention was performed. In this patient with a
diameter of the right CIA of 35 mm and an IIA of 9 mm
with a length of 22 mm, the IBE branch was intentionally
delivered in a secondary branch of the IIA of 6 mm.
Calciﬁcation and tortuosity was mild. There were ﬁve
wound-related complications, including superﬁcial wound
infection (n ¼ 2), wound dehiscence (n ¼ 1), and seroma
(n ¼ 2). The two type Ib endoleaks seen during the surgery
resolved spontaneously. Three patients had buttock clau-
dication: one patient who was treated with a bilateral IBE
had new-onset buttock and thigh claudication at both sides
without loss of patency of the IBE and conﬁrmed with
CT angiography. The other two patients had buttock
claudication at the contralateral side. In one patient, this
can be explained because the contralateral IIA was
embolized and overstented, but in the other patient, the
IIA was patent. One patient mentioned onset of erectile
dysfunction (2.5%), although information on erectile
dysfunction was not always available. Colonic or spinal cord
ischemia was not observed. Other outcome data are listed
in Table II.
Last follow-up. Short-term follow-up was available
for 28 patients who had 32 IBE devices implanted. One
patient died 4 months after the procedure due to conges-
tive heart failure. The mean follow-up of all patients who
had follow-up after 30 days was 5.6 months (range, 1.8-
12.2 months). Two reinterventions were performed: one
patient required the placement of a balloon-expandable
stent for an asymptomatic external iliac limb stenosis, andanother patient had an Amplatzer (St. Jude Medical,
St. Paul, Minn) plug placed in the IIA limb for a new type
Ib endoleak. Initially, this patient was treated according to
the IFU for the device. The primary patency of the IIA
limb device at 6 months was 93.8%. After a mean follow-up
of 6 months, data on 17 treated aneurysms were available.
Two showed a stable diameter, whereas 15 showed a mean
decrease of 3.9 6 2.2 mm (P < .001). Information on
claudication was complete in 21 of 28 patients and on
erectile dysfunction in 18 of 26 male patients. One new
patient suffered from buttock claudication due to an oc-
clusion of the left IIA at the side treated with the IBE
device. This patient was successfully treated with supervised
walking exercise. One new patient reported new erectile
dysfunction without loss of patency.
DISCUSSION
In the present study, we have shown that implantation
of the GORE EXCLUDER IBE device leads to high pro-
cedural success, low reintervention rates, and high short-
term patency. At the 6-month follow-up, IIA patency
was lost in two cases and reinterventions were performed
in two of 46 patients. Iliac branched devices appear to be
a step forward in the era of endovascular treatment of aor-
toiliac aneurysmal disease with preservation of ﬂow to
the ipsilateral IIA. Although the incidence of ischemic
complications due to overstenting or coiling are considered
low, percentages of up to 22% have been described.14
Thus, there seems to be a possible improvement of
results by preservation of iliac ﬂow, especially in young
active patients. These ischemic complications, but also po-
tential future thoracic interventions in case of progression
of disease, justify the preservation of IIAs.15 In the present
series, the contralateral IIA was overstented in six cases,
and it was preserved with a bilateral IBE in ﬁve others.
Which strategy should be preferred, considering clinical
consequences and costs, cannot be concluded from this
case series.
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branched techniques are mainly found in the anatomical re-
quirements. Evidence so far is limited to case series using
the Cook IBD device. Parlani et al12 described the results
of 100 consecutive patients who were enrolled in a pro-
spective database. The procedural success rate was 95%.
At a median follow-up of 21 months, two distal type I
endoleaks occurred. The estimated patency of the internal
iliac branch was 91% at 1 year. Earlier, Karthikesalingsam
et al11 published a systematic analysis of nine studies
including seven series and 196 patients. Technical success
varied between 85% and 100%. Occlusion of the treated
IIA occurred immediately after surgery in 6 patients
(3.1%), at <30 days in 11 patients (5.6%), and during
follow-up in 7 patients (3.6%). In these 24 patients, 50%
experienced buttock claudication. The reintervention rate
was rather low with only 12 patients (6%), although
follow-up is still very limited. Ferrer et al16 reported in
2014 their initial experience with the IBE device in ﬁve pa-
tients. Technical success and iliac branch patency was
100%. One reintervention was necessary concerning a nar-
row aortic bifurcation. Ferrer et al16 considered the dedi-
cated IIA stent on the basis of the GORE EXCLUDER
design and the high conformability of the external iliac
segment as a step forward in iliac branched grafting. The
ﬂexibility of the main body of the device and the option
for repositioning are new in relation to other prostheses.
These features could lead to better results in tortuous iliac
systems and short CIAs. In patients with extensive aneu-
rysmal disease, the preservation of the iliac collateral bed
is essential to prevent spinal cord ischemia when additional
thoracic aneurysm repair is required.14
Results from the present analysis are well in line with
the aforementioned data published on the Cook IBD de-
vice. Although the IFU for IBE is conservative, seven of
the 46 (15.6%) patients were treated outside of the IFU.
The patency of the IIA branch at 6 months was 94% and
the occlusions that occurred did not have evident clinical
effect. One of the IIA branches was intentionally occluded
to treat a type I endoleak. Ipsilateral buttock claudication
was present in only two cases at 30 days and disappeared
during follow-up. The incidence of reported erectile
dysfunction was low and severe ischemic complications
were absent.
The present study has limitations. Because of the retro-
spective design, data were not always complete and espe-
cially clinical data like erectile dysfunction were often
missing and not reported in a standard fashion. Moreover,
the management of the contralateral IIA was not standard-
ized and this can markedly affect clinical outcome. The
mean follow-up time was short. Thirteen hospitals
have participated in this study, introducing biases like
learning curve and differences in case selection. Moreover,
follow-up data were not available for every patient.
These limitations have emphasized the need for a
prospective multicenter registry on the IBE device that is
currently ongoing (Iliac Branch Excluder ReGistry
[IceBERG]; ClinicalTrials.gov NCT02345005).Hopefully, this trial will give us more answers on indication
and outcomes.
On the basis of the current literature, we cannot advise
on which anatomies are suitable or less suitable for iliac
branched devices, and also the sample size of the current
study is too small to study subsets of anatomical variations.
However, we believe that especially in the young active pa-
tient, both IIAs and in the high-risk patient with extensive
aneurysmal disease, at least one IIA should be preserved;
preserving techniques and coiling are indicated to establish
the position of this speciﬁc device. In addition, comparative
trials with competitor devices but also older iliac-preserving
techniques and coiling are indicated to establish the posi-
tion of this speciﬁc device.
CONCLUSIONS
The use of the GORE EXCLUDER IBE device for
CIA aneurysms results in high procedural success and
IIA, patency rates. Prospective data are awaited to establish
the role of the device in the treatment algorithm of CIA
aneurysms.
The help of Elke Mathijssen and Suzanne Holewijn
with the statistical analysis of the data is greatly appreciated,
as is the collaboration of involved investigators in the 13
sites.
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